A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm(R) 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Octapharma
- 31 Aug 2018 Status changed from recruiting to completed.
- 12 Aug 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 12 Aug 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.